Cargando…
Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies
BACKGROUND: To investigate, retrospectively, the role of tumour histotype and antiangiogenic drugs for venous thromboembolism (VTE) development in advanced cancer patients treated in phase I studies. METHODS: Patients enrolled and treated in phase I studies conducted by SENDO (Southern Europe New Dr...
Autores principales: | Mandalà, M, Grosso, F, Vitalini, C, Corradino, I, Sanfilippo, R, Colombini, S, Clerici, M, Labianca, R, De Pascale, A, Marsoni, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419966/ https://www.ncbi.nlm.nih.gov/pubmed/22828607 http://dx.doi.org/10.1038/bjc.2012.325 |
Ejemplares similares
-
Venous thromboembolism in cancer patients: an underestimated major health problem
por: Khalil, Jihane, et al.
Publicado: (2015) -
Venous thromboembolism in children undergoing surgery: incidence, risk factors and related adverse events
por: Mets, Elbert Johann, et al.
Publicado: (2020) -
Venous thromboembolism in multiple myeloma is associated with increased mortality
por: Schoen, Martin W., et al.
Publicado: (2020) -
Liver Injury Associated with Metamizole Exposure: Features of an Underestimated Adverse Event
por: Weber, Sabine, et al.
Publicado: (2021) -
Venous thromboembolism events among RA patients
por: Mansour, Ribhi, et al.
Publicado: (2019)